EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Nivolumab July 1, 2021 Manipulating an Immune Cell May Make Radiation Therapy More Effective, Study... February 12, 2024 Substantial and Durable Overall and Intracranial Activity of Trastuzumab Deruxtecan in... September 27, 2024 Speaking a thousand words – how a cancer image collection is... September 8, 2021 Load more HOT NEWS A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity... Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of... Coping With War and Cancer: How to Take Care of Your... A Deep-Learning Model Predicts the Primary System Origin of Malignant Cells...
